Federal Register Notice: FDA has determined the regulatory review period for Pfizer’s Vfend (voriconaxole) is 2,452 days for the extension of a patent that claims that human drug product. Vfend is indicated for use in the treatment of the following fungal infections: Invasive aspergillosis and serious fungal infections caused by scedosporium apiospermum and fusarium spp., including fusarium solani, in patients intolerant of or refractory to other therapies. To view this notice, click here.
